58 related articles for article (PubMed ID: 38637813)
1. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
Hua X; Xu Q; Wu R; Sun W; Gu Y; Zhu S; Liu X; Lv T; Song Y
J Exp Clin Cancer Res; 2024 Jun; 43(1):164. PubMed ID: 38872221
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis.
Zou C; Shen J; Xu F; Ye Y; Wu Y; Xu S
J Cancer; 2024; 15(11):3510-3530. PubMed ID: 38817865
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5 in Colorectal Cancer: An Insufficiently Explored and Controversial Research Area.
Yang Z; Zhang BL
Gastroenterology; 2023 Dec; 165(6):1581. PubMed ID: 37659670
[No Abstract] [Full Text] [Related]
4. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.
Qu J; Yan H; Hou Y; Cao W; Liu Y; Zhang E; He J; Cai Z
J Hematol Oncol; 2022 Jan; 15(1):8. PubMed ID: 35063010
[TBL] [Abstract][Full Text] [Related]
5. ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer.
An Y; Duan H
J Ovarian Res; 2024 Apr; 17(1):84. PubMed ID: 38637813
[TBL] [Abstract][Full Text] [Related]
6. ALKBH5-mediated upregulation of CPT1A promotes macrophage fatty acid metabolism and M2 macrophage polarization, facilitating malignant progression of colorectal cancer.
Sun M; Yue Y; Wang X; Feng H; Qin Y; Chen M; Wang Y; Yan S
Exp Cell Res; 2024 Apr; 437(1):113994. PubMed ID: 38479704
[TBL] [Abstract][Full Text] [Related]
7. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway.
Jiang Y; Wan Y; Gong M; Zhou S; Qiu J; Cheng W
J Cell Mol Med; 2020 Jun; 24(11):6137-6148. PubMed ID: 32329191
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
10. ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner.
Chen J; Ye M; Bai J; Gong Z; Yan L; Gu D; Hu C; Lu F; Yu P; Xu L; Wang Y; Tian Y; Tang Q
J Transl Med; 2023 Oct; 21(1):741. PubMed ID: 37858219
[TBL] [Abstract][Full Text] [Related]
11. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment.
Lin W; Luo Y; Wu J; Zhang H; Jin G; Guo C; Zhou H; Liang H; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935565
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses.
Li J; Chen D; Shen M
Front Med (Lausanne); 2022; 9():869010. PubMed ID: 35402443
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression That Is Related to Cell Proliferation, Metastasis and Tumor-Infiltrating Immune Cells.
Zhou L; Li H; Cai H; Liu W; Pan E; Yu D; He S
Front Oncol; 2022; 12():809589. PubMed ID: 35299748
[TBL] [Abstract][Full Text] [Related]
14. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
